Atherosclerosis Research

Atherosclerosis is a disease of the arterial system that is characterized by the accumulation of fatty deposits within arterial walls, known as 'atherosclerotic plaques'.

Atherosclerosis Research Products Targets

Products for Atherosclerosis Research - Page 28

Cat.No. Product Name Information/Activity
BCC2268 GW501516 GW 501516 is a PPARδ agonist with an EC50 of 1.1 nM.
BCC1573 FH535 FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.
BCC7688 GSK 0660 GSK0660 is a potent antagonist of PPARβ and PPARδ, with IC50s of 155 nM for both isoforms.
BCC2263 GSK3787 GSK3787 is as a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ.
BCC7014 Ciglitazone 74772-77-3
BCC7786 LG 100754 LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR.
BCC7268 nTZDpa 118414-59-8
BCC2278 Pioglitazone HCl Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
BCC7321 15-deoxy-Δ-12,14-Prostaglandin J2 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM.
BCC2264 Rosiglitazone Rosiglitazone (BRL 49653) is a selective PPARγ activator with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively.